Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma

References

• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. JCO. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17(1):20–47.e30.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.
   PubMed Web of Science ®Google Scholar
• Perseghin P, Terruzzi E, Dassi M, et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci. 2009;41(1):33–37.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. JCO. 2014;32(31):3490–3496.
   PubMed Web of Science ®Google Scholar
• Mollee P, Pereira D, Nagy T, et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant. 2002;30(5):273–278.
   PubMed Web of Science ®Google Scholar
• Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant. 2012;47(4):483–487.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Varela NP, Bredeson C, et al. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Curr Oncol. 2016;23(4):e409–430.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. JCO. 2000;18(6):1360–1377.
   PubMed Web of Science ®Google Scholar
• Center for International Blood and Marrow Transplant Research. Forms manual: Post-TED (form 2450), A00425, version 2.0 (8/01/2012). [cited 2018 Feb]. Available from: http://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents/post-ted-instruction.pdf.
   Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
   Web of Science ®Google Scholar
• Cheung MC, Hay AE, Crump M, et al. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015;107. doi:10.1093/jnci/djv106
   Google Scholar
• To LB, Levesque J-P, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530–4540.
   PubMed Web of Science ®Google Scholar
• Sheppard D, Bredeson C, Allan D, et al. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2012;18(8):1191–1203.
   PubMed Web of Science ®Google Scholar
• van Gorkom G, Finel H, Giebel S, et al. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apheresis. 2017;32(5):295–301.
   PubMed Web of Science ®Google Scholar
• Rossi G, Skert C, Morello E, et al. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. Hematol Oncol. 2015;33(3):125–132.
   PubMed Web of Science ®Google Scholar
• Kim SS, Renteria AS, Steinberg A, Banoff K, et al. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. Cytotherapy. 2014;16(11):1584–1589.
   PubMed Web of Science ®Google Scholar
• Mohty M, Azar N, Chabannon C, et al. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. 2018;53(3):246–254.
   PubMed Web of Science ®Google Scholar
• Hosing C, Smith V, Rhodes B, et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. 2011;51(6):1300–1313.
   PubMed Web of Science ®Google Scholar
• Gambell P, Herbert K, Dickinson M, et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1000 collections. Biol Blood Marrow Transplant. 2012;18(5):763–772.
   PubMed Web of Science ®Google Scholar
• Olivieri A, on behalf of the Italian Group for Stem Cell Transplantation (GITMO), Marchetti M, Lemoli R, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–351.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin’s lymphoma. Hematol J. 2000;1(6):367–373.
   PubMedGoogle Scholar
• Varmavuo V, Mantymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol. 2012;89(2):128–135.
   PubMed Web of Science ®Google Scholar
• Alexander ET, Towery JA, Miller AN, et al. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Transfusion. 2011;51(9):1995–2000.
   PubMed Web of Science ®Google Scholar
• Valtola J, Silvennoinen R, Ropponen A, et al. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion. 2016;56(6):1394–1401.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. JCO. 2000;18(1):43–53.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–3969.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91(9):3148–3155.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):967–972.
   PubMed Web of Science ®Google Scholar
• Jiang L, Malik S, Litzow M, et al. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion. 2012;52(3):542–548.
   PubMed Web of Science ®Google Scholar